Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends
Key Points
AbbVie has increased its dividend by more than 330% since 2013.
It has a robust pipeline of drugs in development and growing revenue, too.
- 10 stocks we like better than AbbVie ›
It's smart to seek dividend income from your investments because it can be used to help pay living expenses or to buy more stock. A solid dividend-paying stock to consider is pharmaceutical company AbbVie (NYSE: ABBV), which was spun off from Abbott Laboratories in 2013. The stock recently sported a 3.38% dividend yield, far above the average yield of 1.1% for stocks in the S&P 500.
If you're looking for, say, $10,000 in annual dividend income, how many shares of AbbVie do you need to buy?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Well, start by noting that the company's last quarterly dividend payment was $1.73 per share. The yearly run rate, then, is $6.92 per share. So divide $10,000 by $6.92, and you'll get 1,445 -- the number of shares you'd need. With the stock recently trading around $205 per share (as of March 24), those 1,445 shares would cost you a hefty $296,225. (Fortunately, you can always buy fewer than 1,445 shares!)
One reason to consider investing in AbbVie is that it's a rather reliable dividend payer -- and dividend grower. Since 2013, it has upped its payout by more than 330%. Better still, when you combine its history with that of Abbott Labs, you'll see that it has increased its payout annually for more than 25 years. So the $10,000 (or other sum) that you collect in dividends this year could be much more after a few years.
The dividend is not the only reason to consider AbbVie. It's a strong grower in general, with its stock averaging annual gains of 16.2% over the past decade. Its 2025 revenue was up 8.6% over the year before -- despite its having lost patent protection for its blockbuster drug, Humira. Its pipeline of 90-plus drugs in development is promising, too.
AbbVie's stock is reasonably priced, with a recent forward-looking price-to-earnings (P/E) ratio of 14, a bit above the five-year average of 13.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $497,659!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,095,404!*
Now, it’s worth noting Stock Advisor’s total average return is 912% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 27, 2026.
Selena Maranjian has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
Recommended Articles
